

SCIENTIFIC REPORTS



OPEN

Bub1 is required for maintaining cancer stem cells in breast cancer cell lines

Jeong Yoon Han^{1,*}, Yu Kyeong Han^{1,*}, Ga-Young Park^{1,2}, Sung Dae Kim¹, Joong Sun Kim¹, Wol Soon Jo¹ & Chang Geun Lee¹

Received: 28 May 2015

Accepted: 06 October 2015

Published: 02 November 2015

Breast cancer is a leading cause of death among women worldwide due to therapeutic resistance and cancer recurrence. Cancer stem cells are believed to be responsible for resistance and recurrence. Many efforts to overcome resistance and recurrence by regulating cancer stem cells are ongoing. Bub1 (Budding uninhibited by benzimidazoles 1) is a mitotic checkpoint serine/threonine kinase that plays an important role in chromosome segregation. Bub1 expression is correlated with a poor clinical prognosis in patients with breast cancer. We identified that depleting Bub1 using shRNAs reduces cancer stem cell potential of the MDA-MB-231 breast cancer cell line, resulting in inhibited formation of xenografts in immunocompromised mice. These results suggest that Bub1 may be associated with cancer stem cell potential and could be a target for developing anti-breast cancer stem cell therapies.

Breast cancer is one of the most common cancers and is a leading cause of death among women worldwide due to therapeutic resistance and cancer recurrence^{1–3}. Several possible mechanisms have been proposed to explain resistance of cancers, including breast cancer to anti-cancer therapies and cancer recurrence. One is the cancer stem cell (CSC) theory in which small cancer cell subsets, which are capable of self-renewal, become more tumorigenic and resistant to anti-cancer therapeutics than others^{4–6}. Thus, many efforts have been devoted to develop CSC-targeted therapies^{7–10}.

Several markers and methods have been suggested to define breast CSCs, such as surface expression of CD24^{low}CD44^{high}, CXCR4⁺, Hoechst 33342 exclusion activity (side population), and aldehyde dehydrogenase activity^{11–15}. Among them, CD24/CD44 staining is the most widely used method to identify breast CSCs. CD44, a type I transmembrane glycoprotein, is the major cellular receptor for hyaluronan (HA). Interactions between CD44 and HA are critical for expansion, differentiation, and pluripotency of stem cells including CSCs and also for cancer progression by modulating cell adhesion, migration, and invasion^{16–19}. CD44 cooperates with HA-mediated motility (RHAMM or CD168) to deliver signals from extracellular HA, which is overexpressed in many advanced cancers including breast cancer^{20–23}. RHAMM is an HA cell surface receptor and is also a cytoplasmic and nuclear protein that interacts with interphase microtubules, the mitotic spindle, and centrosomes^{24–26}.

Mitotic kinases and mitotic checkpoint proteins play key roles in cell division and maintenance of chromosome stability. Thus, mis-regulation of these processes may result in tumorigenesis. Furthermore, mitosis plays important roles balancing stem cells between self-renewal and differentiation to progenitor cells by regulating symmetric and asymmetric division^{27,28}. These proteins have been shown to play an important role maintaining the CSC population and could be a potential therapeutic target for CSC-targeted therapies. Plk1 is a key mitotic regulator that has been identified as a potential therapeutic target for eliminating breast and colon CSCs^{29,30}. CSCs are maintained by Aurora kinase A (AurA) and inhibiting AurA has been viewed as effective approach to target the CSC population in various

¹Research Center, Dongnam Institute of Radiological & Medical Sciences, Busan 619-953, ROK. ²Department of Molecular Biology, College of Natural Sciences, Pusan National University, Busan 609-735, ROK. *These authors contributed equally to this work. Correspondence and requests for materials should be addressed to C.G.L. (email: cglee@dirams.re.kr)




Figure 1. Depleting Bub1 reduces xenograft forming ability of MDA-MB-231 cells in immunocompromised mice. (a) The levels of Bub1 expression in the Bub1-depleted MDA-MB-231 stable cell lines were measured by Western blot analysis. (b) 2×10^3 cells of each cell lines were seeded onto 6 well plates. Cell numbers were counted at the indicated timpoints. Data were shown as mean values \pm SD. (c,d) Control (shLuc) and Bub1-depleted (shBub1 #1 & #2) MDA-MB-231 cells were injected subcutaneously into the right flanks of Balb/c-nu mice and allowed to form xenografts. Tumor formation was examined 30 days later.

cancers^{31–33}. Glioblastoma initiating cells have lethal kinetochore-microtubule attachment defects that are suppressed by BubR1. Thus, BubR1 may be a therapeutic target for glioblastoma CSCs³⁴. Besides the involvement of mitotic kinases and mitotic checkpoint proteins in the maintenance of CSCs, genomic instability and polyploidy, which are induced by defects in mitotic kinases or mitotic checkpoint proteins, contribute to generating cancer-stem-like cells^{35,36}.

Bub1 is a mitotic checkpoint protein that is overexpressed in breast cancer and other cancers, and its expression correlates with a poor clinical prognosis^{37–43}. We identified that depleting Bub1 in the MDA-MB-231 a breast cancer cell line prevents generation of xenografts in immunocompromised mice due to reduced CSC potential in Bub1-depleted cells and resulted in radiosensitization. Reduced CSC population and radiosensitization by Bub1 depletion were also observed in the MCF7 cells. These results suggest that Bub1, like other mitotic regulators, such as AurA, BubR1, and Plk1, is associated with CSC potential and may be a target for developing of anti-CSC therapy.

Results

Depleting Bub1 reduces xenograft forming ability of MDA-MB-231 cells in immunocompromised mice. We used shRNAs targeting Bub1 (shBub1) to investigate the roles of Bub1 in breast cancer development and therapy. After transfection of MDA-MB-231 cells with control shRNA (shLuc), shBub1-#1 or shBub1-#2, stable clones were obtained by puromycin selection. Bub1 depletion in the stable clones was verified by western blot analysis and the reduced expression of Bub1 was maintained during this study (Fig. 1a). Bub1 depletion did not induce significant enhancement or reduction in cell proliferation (Fig. 1b). However, Bub1-depleted MDA-MB-231 cells did not generate xenografts in immunocompromised mice (Fig. 1c,d). Control cells (shLuc) formed xenografts efficiently (8/10 head) but Bub1-depleted MDA-MB-231 cells did not generate xenografts. These results suggest that depleting Bub1 reduces xenograft forming ability of MDA-MB-231 cells in immunocompromised mice.

Depleting Bub1 reduces the CSC potential of MDA-MB-231 and MCF7 cells. A xenograft assay is widely used in immunocompromised mice to evaluate CSC potential. Thus, we investigated whether Bub1-depleted cells had reduced CSC potential. A 3D Matrigel sphere-forming assay was used to evaluate CSC potential. Bub1-depleted cells generated smaller and fewer spheres in 3D Matrigel culture than those in control cells (Fig. 2a). CD24 and CD44 surface staining was used to estimate the CSC population of breast cancer cells. FACS analysis showed that the CD24^{low}CD44^{high} population, which is believed to contain breast CSC subsets, was reduced in Bub1-depleted cells compared to that in control




Figure 2. Depleting Bub1 reduces cancer stem cell (CSC) potential of MDA-MB-231 cells.

(a) Approximately 5×10^3 cells were cultured using a serum-free MammoCult Human Medium kit containing 2.5% Matrigel, and images were obtained 10–14 days later. (b) FACS analysis was performed to evaluate the CD24^{low}CD44^{high} CSC population. % of CD24^{low}CD44^{high} population is shown. (c,d) The Matrigel invasion assay was performed, the cells were stained with crystal violet, and images were taken for counting. The number of cells invading the Matrigel was normalized by setting the number of control cells invading the Matrigel to 100%. Data were shown as mean \pm Standard Deviation (SD). Statistical significance compared to the control is shown.

cells (Fig. 2b). Enhanced invasion ability is a CSC characteristic. Depleting Bub1 consistently reduced invasion by MDA-MB-231 cells in the Matrigel invasion assay (Fig. 2c,d). Reduced CSC population by Bub1 depletion was further confirmed in MCF7 cells. Bub1 depletion in MCF7 cells did not result in significant reduction in cell proliferation (Fig. 3a,b). Bub1-depleted MCF7 cells were analyzed by FACS analysis using anti-CD24 and CD44 antibodies. Although MCF7 cells have much less CSC population than MDA-MB-231 cells, Bub1 depletion reduced the CD24^{low}CD44^{high} population (Fig. 3c). Taken together with the xenograft assay results, these results suggest that depleting Bub1 reduced the CSC potential of breast cancer cell lines.

Reduced CSC potential correlates with alterations in the RHAMM-GSK3 β pathway. We further investigated how depleting Bub1 resulted in reduced CSC potential. RHAMM plays diverse roles on the cell surface and in the nucleus^{26,44,45}. RHAMM influences maintenance of CSCs by regulating GSK3 β activity and also is involved in mitotic spindle integrity^{45,46}. Since Bub1 is a mitotic checkpoint protein involved in regulating the kinetochore-microtubule interaction during mitosis, we investigated whether Bub1 depletion modulate the RHAMM-GSK3 β pathway. RHAMM expression was reduced and inhibitory phosphorylation of GSK3 β was increased in Bub1-depleted MDA-MB-231 cells compared to those in control cells, indicating that depleting Bub1 may affect the RHAMM-GSK3 β signaling pathway (Fig. 4a). These results were further confirmed in Bub1-depleted MCF7 cells (Fig. 3d). In the next step, we used RHAMM shRNAs and a GSK3 β inhibitor to investigate the relationship between RHAMM and GSK3 β . Depleting RHAMM with shRNAs enhanced GSK3 β inhibitory phosphorylation but the GSK3 β inhibitor did not modulate RHAMM expression (Fig. 4b,c). These findings suggest that depleting Bub1 decreased RHAMM expression, which, in turn, enhanced inhibitory phosphorylation of GSK3 β .

Reduced CSC potential by depleting Bub1 results in enhanced sensitivity to irradiation. CSCs are a main anti-cancer therapy resistance mechanism. Thus, we investigated whether reduced CSC potential of Bub1-depleted MDA-MB-231 or MCF7 cells results in sensitization to anti-cancer therapies. Control and Bub1-depleted MDA-MB-231 or MCF7 cells were compared for their sensitivity to irradiation. Clonogenic assays showed that sensitivity to irradiation was enhanced in Bub1-depleted cells




Figure 3. Depleting Bub1 reduces cancer stem cell (CSC) population of MCF7 cells. (a) The levels of Bub1 expression in the Bub1-depleted MCF7 stable cell lines were measured by Western blot analysis. (b) 5×10^3 cells of each cell lines were seeded onto 6 well plates. Cell numbers were counted at the indicated timpoints. Data were shown as mean values \pm SD. (c) FACS analysis was performed to evaluate the CD24^{low}CD44^{high} CSC population. % of CD24^{low}CD44^{high} population is shown. (d) Cell lysates of control and Bub1-depleted MCF7 cells were subjected to Western blot analysis using p-GSK3 β , GSK3 β , and RHAMM antibodies.




Figure 4. Depleting Bub1 enhances inhibitory phosphorylation of glycogen synthase kinase-3 β (GSK3 β) through reduced RHAMM expression. (a) Cell lysates of control and Bub1-depleted MDA-MB-231 cells were subjected to Western blot analysis using p-GSK3 β , GSK3 β , and RHAMM antibodies. (b) Cell lysates of control and RHAMM-depleted MDA-MB-231 cells were subjected to Western blot analysis using p-GSK3 β , GSK3 β , and RHAMM antibodies. (c) MDA-MB-231 cells were treated with the indicated concentration of a GSK3 β inhibitor, and cell lysates were subjected to Western blot analysis using p-GSK3 β , GSK3 β , and RHAMM antibodies.

compared to that in control cells (Fig. 5a,c). Enhanced cell death in Bub1-depleted cells by irradiation was further confirmed by enhanced PARP and caspase-3 cleavage (Fig. 5b,d).

Discussion

CSCs, like stem cells, are maintained through a balance between symmetric and asymmetric division during mitosis. Deregulation of mitotic progression may influence the balance between symmetric and asymmetric division, resulting in changes in the CSC population. This finding suggests that mitotic kinases or mitotic checkpoint proteins may be good targets for developing anti-CSC therapies. AurA, Plk1, and BubR1 are consistently reported to be good targets for developing anti-CSC therapies^{29–34}. As a mitotic checkpoint, Bub1 plays important roles in regulating mitosis by interacting with BubR1 and kinetochores. Our results support the possibility that Bub1 can be a target for developing anti-CSC therapies at least in breast cancers, where Bub1 expression correlates with poor clinical prognosis^{38–40,42}.




Figure 5. Depleting Bub1 sensitizes breast cancer cells to irradiation. (a,c) Control and Bub1-depleted MDA-MB-231 or MCF7 cells were irradiated, and clonogenic assays were performed. Data were shown as mean values \pm SD. Statistical significance compared to the control is shown. (b,d) Control and Bub1-depleted MDA-MB-231 or MCF7 cells were irradiated, and the cells were harvested at the indicated timepoints. Cell lysates were prepared and subjected to Western blot analysis with the indicated antibodies.

Although several mitotic kinases and mitotic checkpoint proteins were reported to be involved in maintaining stem cells or cancer stem cells, specific mechanisms remains poorly understood. Ding *et al.* showed that brain tumor-initiating cells (BTIC) have kinetochore-microtubule (KT-MT) attachment defects and BubR1, specifically GLE2p-binding sequence (GLEBS) domain activity, is required to overcome the defects³⁴. In mammary stem/progenitor cell fate determination, it was reported that AurA modulates the balance between the luminal and basal cell lineages by regulating the orientation of the mitotic spindle⁴⁷. These results suggest that it may be important to regulate mitotic microtubules in maintaining stem cell population either in normal organs and cancers.

During mitosis, Bub1 plays several roles, such as recruiting the mitotic checkpoint proteins to the kinetochore, mounting the mitotic checkpoint response and chromosome congression. Bub1 has several protein-protein interaction domains, such as Tetratricopeptide repeat (TPR), GLEBS and a conserved region (CDI) domains involved in recruiting the mitotic checkpoint proteins to the kinetochore and the spindle checkpoint function, and Ser/Thr kinase domain involved in chromosome congression⁴⁸. We need to figure out which domain or activity is involved in modulating CSC population. As described above, GLEBS domain of BubR1 is required to maintain brain tumor-initiating cells (BTIC)³⁴. Since Bub1 also has GLEBS domain similar to that of BubR1, it may be interesting to investigate whether GLEBS domain of Bub1 is required to maintain breast cancer stem cells.

RHAMM functions at the cell surface and in the nucleus. Reduced expression of RHAMM is associated with decreased CSC self-renewal and embryonic stem cell pluripotency^{46,49}. However, it is unclear whether cell surface or nuclear RHAMM is required to maintain self-renewal of stem cells or CSC. Nuclear RHAMM regulates stability of the mitotic spindle, which is involved in chromosome segregation through interactions with kinetochores. As Bub1 is located at the kinetochores during mitosis, depleting Bub1 may influence RHAMM expression by affecting the mitotic spindles and destabilizing RHAMM. Further investigation may be needed to determine how depleting Bub1 affects RHAMM expression and whether cell surface or nuclear RHAMM is important for CSC self-renewal.

As the CSC breast cancer populations are an obstacle to therapeutics, molecules required for CSC maintenance may be promising targets. Our results and previous reports support the possibility that regulation of kinetochore-mitotic microtubule (KT-MT) attachment may be involved in maintaining stem cell or CSC population and can be a target for developing anti-breast CSC therapies.

Materials and Methods

Ethics statement. All the methods were carried out in accordance with the approved guidelines at Dongnam Institute of Radiological & Medical Sciences. All experiment protocols were approved by Dongnam Institute of Radiological & Medical Sciences. Animal studies were conducted in accordance with the guidelines established by the Committee on Use and Care of Animals of Dongnam Institute of Radiological & Medical Sciences. Animals were treated humanely in accordance with the Ministry of Food and Drug Safety on the ethical use of animals.

Plasmid construction, transfection and cell culture. Sense and antisense oligonucleotides for shRNAs targeting human Bub1 (5'-GGAAGTGCCTCATGCTGAAGA-3', 5'-GCTGCACAACCTTGCGTCTACA-3', 5'-GGGACTGTTGATGCTCCAAAC-3') were generated, annealed, and cloned into the pSuper.puro vector, according to the manufacturer's instructions (Oligoengine, Seattle, WA, USA). For Bub1-depleted stable clones, MDA-MB-231 or MCF7 cells were transfected with each shRNA, subject to puromycin selection 36 hrs after transfection. Bub1 expression of stably transfected clones was verified by western blot analysis. shRNAs targeting human RHAMM (TRCN0000061555 and TRCN0000333646) were purchased from Sigma-Aldrich (St. Louis, MO, USA). MDA-MB-231 and MCF7 cells were purchased from the American Type Culture Collection (Manassas, VA, USA). Cell culture, transfection, and irradiation were performed as described previously^{50,51}.

Three-dimensional (3D) Matrigel culture, clonogenic assay and quantitative RT-PCR assay. Cells in 3D Matrigel culture were grown in eight-chambered CultureSlides (BD Biosciences, Bedford, MA, USA) at a density of 5,000 viable cells/400 μ l using the serum-free MammoCult Human Medium Kit (STEMCELL Technologies, Vancouver, BC, Canada) containing 2.5% Matrigel Matrix (BD Biosciences), according to the manufacturer's instructions. Images were obtained 10–14 days later. The clonogenic assay was performed as described previously⁵². Surviving fractions were normalized by setting the percentage of surviving colonies in control wells to 1.

Xenograft assay. Animal studies were conducted in accordance with the guidelines established by the Committee on Use and Care of Animals of Dongnam Institute of Radiological & Medical Sciences. Animals were treated humanely in accordance with the Ministry of Food and Drug Safety on the ethical use of animals. Control and Bub1-depleted MDA-MB-231 cells were inoculated subcutaneously into the right flanks of Balb/c-nu mice (6-weeks-old), and tumor growth was examined.

Flow cytometry analysis. CD24-FITC and CD44-APC antibodies (BD Pharmingen, San Diego, CA, USA) were used to measure the CD24^{low}CD44^{high} CSC-population. Results were analyzed on a Becton Dickinson FACS Aria (Franklin Lakes, NJ, USA) using FACS Diva software.

Western blot analysis. Protein samples were separated by sodium dodecyl sulfate-polyacrylamide (SDS) gel electrophoresis, transferred to a nitrocellulose filter, blocked, and analyzed with Bub1, poly-ADP ribose polymerase (PARP), cleaved PARP (Santa Cruz Biotechnology, Santa Cruz, CA, USA), RHAMM (Novus Biologicals, Littleton, CO, USA), caspase-3, cleaved caspase-3, p-glycogen synthase kinase 3 β (GSK3 β) (Cell Signaling Technology, Danvers, MA, USA), and actin (Sigma) antibodies.

Invasion assay. Cell culture inserts (BD Biosciences) were used to evaluate differences in invasiveness. The upper membranes of the cell culture inserts were coated with a mixture (1:10 ratio) of Matrigel and Opti-MEM[®]I Reduced Serum Medium (Life Technologies, Grand Island, NY, USA) for 1.5 hr in 24-well plates. The cell culture inserts were rehydrated with serum-free DMEM for 1 hr. Approximately 2.5×10^4 cells were suspended in serum-free DMEM and seeded into the upper chambers of the cell culture inserts. DMEM with 10% fetal bovine serum was added to the lower chambers. The cell culture inserts containing cells were incubated at 37°C for 24 hr, and the inserts were removed. The cells that had passed through the membranes were fixed in 100% methanol and stained with 0.1% crystal violet for 10 min. The upper surfaces of the inserts were wiped with a swab, and the membranes were isolated from the inserts to prepare slides. Invading cells were observed and photographed using an Eclipse TS100 inverted microscope (Nikon, Tokyo, Japan) and the Image-Pro Plus program (MediaCybernetics, Bethesda, MD, USA).

Statistics. Results were expressed as mean \pm Standard Deviation (SD). Student's t-test was used to compare values of test and control samples.

References

1. Lech, R. & Przemyslaw, O. Epidemiological models for breast cancer risk estimation. *Ginekol Pol* **82**, 451–454 (2011).
2. Marusyk, A. & Polyak, K. Tumor heterogeneity: causes and consequences. *Biochim Biophys Acta* **1805**, 105–117, doi: 10.1016/j.bbcan.2009.11.002 (2010).
3. Merlo, L. M., Pepper, J. W., Reid, B. J. & Maley, C. C. Cancer as an evolutionary and ecological process. *Nat Rev Cancer* **6**, 924–935, doi: 10.1038/nrc2013 (2006).
4. O'Brien, C. A., Kreso, A. & Dick, J. E. Cancer stem cells in solid tumors: an overview. *Semin Radiat Oncol* **19**, 71–77, doi: 10.1016/j.semradonc.2008.11.001 (2009).

5. Winqvist, R. J., Furey, B. F. & Boucher, D. M. Cancer stem cells as the relevant biomass for drug discovery. *Curr Opin Pharmacol* **10**, 385–390, doi: 10.1016/j.coph.2010.06.008 (2010).
6. Zhou, B. B. *et al.* Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. *Nat Rev Drug Discov* **8**, 806–823, doi: 10.1038/nrd2137 (2009).
7. Dean, M., Fojo, T. & Bates, S. Tumour stem cells and drug resistance. *Nat Rev Cancer* **5**, 275–284, doi: 10.1038/nrc1590 (2005).
8. Frank, N. Y., Schatton, T. & Frank, M. H. The therapeutic promise of the cancer stem cell concept. *J Clin Invest* **120**, 41–50, doi: 10.1172/JCI41004 (2010).
9. Gupta, P. B. *et al.* Identification of selective inhibitors of cancer stem cells by high-throughput screening. *Cell* **138**, 645–659, doi: 10.1016/j.cell.2009.06.034 (2009).
10. Park, C. Y., Tseng, D. & Weissman, I. L. Cancer stem cell-directed therapies: recent data from the laboratory and clinic. *Mol Ther* **17**, 219–230, doi: 10.1038/mt.2008.254 (2009).
11. Abraham, B. K. *et al.* Prevalence of CD44+/CD24–/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. *Clin Cancer Res* **11**, 1154–1159 (2005).
12. Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J. & Clarke, M. F. Prospective identification of tumorigenic breast cancer cells. *Proc Natl Acad Sci USA* **100**, 3983–3988, doi: 10.1073/pnas.0530291100 (2003).
13. Ponti, D., Zaffaroni, N., Capelli, C. & Daidone, M. G. Breast cancer stem cells: an overview. *Eur J Cancer* **42**, 1219–1224, doi: 10.1016/j.ejca.2006.01.031 (2006).
14. Sheridan, C. *et al.* CD44+/CD24– breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. *Breast Cancer Res* **8**, R59, doi: 10.1186/bcr1610 (2006).
15. Shipitsin, M. *et al.* Molecular definition of breast tumor heterogeneity. *Cancer Cell* **11**, 259–273, doi: 10.1016/j.ccr.2007.01.013 (2007).
16. Kosaki, R., Watanabe, K. & Yamaguchi, Y. Overproduction of hyaluronan by expression of the hyaluronan synthase Has2 enhances anchorage-independent growth and tumorigenicity. *Cancer Res* **59**, 1141–1145 (1999).
17. Naor, D., Nedvetzki, S., Golan, I., Melnik, L. & Faitelson, Y. CD44 in cancer. *Crit Rev Clin Lab Sci* **39**, 527–579, doi: 10.1080/10408360290795574 (2002).
18. Stratford, A. L. *et al.* Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancers. *Stem Cells* **30**, 1338–1348, doi: 10.1002/stem.1128 (2012).
19. Toole, B. P. Hyaluronan promotes the malignant phenotype. *Glycobiology* **12**, 37R–42R (2002).
20. Adamia, S., Maxwell, C. A. & Pilarski, L. M. Hyaluronan and hyaluronan synthases: potential therapeutic targets in cancer. *Curr Drug Targets Cardiovasc Haematol Disord* **5**, 3–14 (2005).
21. Assmann, V., Marshall, J. F., Fieber, C., Hofmann, M. & Hart, I. R. The human hyaluronan receptor RHAMM is expressed as an intracellular protein in breast cancer cells. *J Cell Sci* **111** (Pt 12), 1685–1694 (1998).
22. Telmer, P. G., Tolg, C., McCarthy, J. B. & Turley, E. A. How does a protein with dual mitotic spindle and extracellular matrix receptor functions affect tumor susceptibility and progression? *Commun Integr Biol* **4**, 182–185, doi: 10.4161/cib.4.2.14270 (2011).
23. Wang, C. *et al.* The overexpression of RHAMM, a hyaluronan-binding protein that regulates ras signaling, correlates with overexpression of mitogen-activated protein kinase and is a significant parameter in breast cancer progression. *Clin Cancer Res* **4**, 567–576 (1998).
24. Assmann, V., Jenkinson, D., Marshall, J. F. & Hart, I. R. The intracellular hyaluronan receptor RHAMM/IHABP interacts with microtubules and actin filaments. *J Cell Sci* **112** (Pt 22), 3943–3954 (1999).
25. Joukov, V. *et al.* The BRCA1/BARD1 heterodimer modulates ran-dependent mitotic spindle assembly. *Cell* **127**, 539–552, doi: 10.1016/j.cell.2006.08.053 (2006).
26. Maxwell, C. A. *et al.* RHAMM is a centrosomal protein that interacts with dynein and maintains spindle pole stability. *Mol Biol Cell* **14**, 2262–2276, doi: 10.1091/mbc.E02-07-0377 (2003).
27. Chang, J. T. & Reiner, S. L. Asymmetric division and stem cell renewal without a permanent niche: lessons from lymphocytes. *Cold Spring Harb Symp Quant Biol* **73**, 73–79, doi: 10.1101/sqb.2008.73.008 (2008).
28. Lathia, J. D. *et al.* Distribution of CD133 reveals glioma stem cells self-renew through symmetric and asymmetric cell divisions. *Cell Death Dis* **2**, e200, doi: 10.1038/cddis.2011.80 (2011).
29. Francescangeli, F. *et al.* Proliferation state and polo-like kinase1 dependence of tumorigenic colon cancer cells. *Stem Cells* **30**, 1819–1830, doi: 10.1002/stem.1163 (2012).
30. Hu, K., Law, J. H., Fotovati, A. & Dunn, S. E. Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells. *Breast Cancer Res* **14**, R22, doi: 10.1186/bcr3107 (2012).
31. Cammareri, P. *et al.* Aurora-a is essential for the tumorigenic capacity and chemoresistance of colorectal cancer stem cells. *Cancer Res* **70**, 4655–4665, doi: 10.1158/0008-5472.CAN-09-3953 (2010).
32. Chefetz, I., Holmberg, J. C., Alvero, A. B., Visintin, I. & Mor, G. Inhibition of Aurora-A kinase induces cell cycle arrest in epithelial ovarian cancer stem cells by affecting NFκB pathway. *Cell Cycle* **10**, 2206–2214 (2011).
33. Mannino, M., Gomez-Roman, N., Hoehegger, H. & Chalmers, A. J. Differential sensitivity of Glioma stem cells to Aurora kinase A inhibitors: implications for stem cell mitosis and centrosome dynamics. *Stem Cell Res* **13**, 135–143, doi: 10.1016/j.scr.2014.05.001 (2014).
34. Ding, Y. *et al.* Cancer-Specific requirement for BUB1B/BUBR1 in human brain tumor isolates and genetically transformed cells. *Cancer Discov* **3**, 198–211, doi: 10.1158/2159-8290.CD-12-0353 (2013).
35. Liang, Y. *et al.* Stem-like cancer cells are inducible by increasing genomic instability in cancer cells. *J Biol Chem* **285**, 4931–4940, doi: 10.1074/jbc.M109.048397 (2010).
36. Zhang, S. *et al.* Generation of cancer stem-like cells through the formation of polyploid giant cancer cells. *Oncogene* **33**, 116–128, doi: 10.1038/onc.2013.96 (2014).
37. Bie, L. *et al.* The accuracy of survival time prediction for patients with glioma is improved by measuring mitotic spindle checkpoint gene expression. *PLoS One* **6**, e25631, doi: 10.1371/journal.pone.0025631 (2011).
38. Finetti, P. *et al.* Sixteen-kinase gene expression identifies luminal breast cancers with poor prognosis. *Cancer Res* **68**, 767–776, doi: 10.1158/0008-5472.CAN-07-5516 (2008).
39. Glinsky, G. V., Berezovska, O. & Glinskii, A. B. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. *J Clin Invest* **115**, 1503–1521, doi: 10.1172/JCI23412 (2005).
40. Nakagawa, T. *et al.* A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy. *PLoS One* **3**, e2318, doi: 10.1371/journal.pone.0002318 (2008).
41. Shigeishi, H. *et al.* Correlation of human Bub1 expression with tumor-proliferating activity in salivary gland tumors. *Oncol Rep* **15**, 933–938 (2006).
42. Sotiriou, C. *et al.* Breast cancer classification and prognosis based on gene expression profiles from a population-based study. *Proc Natl Acad Sci USA* **100**, 10393–10398, doi: 10.1073/pnas.1732912100 (2003).

43. Takagi, K. *et al.* BUB1 immunolocalization in breast carcinoma: its nuclear localization as a potent prognostic factor of the patients. *Horm Cancer* **4**, 92–102, doi: 10.1007/s12672-012-0130-x (2013).
44. Maxwell, C. A., McCarthy, J. & Turley, E. Cell-surface and mitotic-spindle RHAMM: moonlighting or dual oncogenic functions? *J Cell Sci* **121**, 925–932, doi: 10.1242/jcs.022038 (2008).
45. Tolg, C. *et al.* RHAMM promotes interphase microtubule instability and mitotic spindle integrity through MEK1/ERK1/2 activity. *J Biol Chem* **285**, 26461–26474, doi: 10.1074/jbc.M110.121491 (2010).
46. Shigeishi, H. *et al.* Maintenance of stem cell self-renewal in head and neck cancers requires actions of GSK3beta influenced by CD44 and RHAMM. *Stem Cells* **31**, 2073–2083, doi: 10.1002/stem.1418 (2013).
47. Regan, J. L. *et al.* Aurora A kinase regulates mammary epithelial cell fate by determining mitotic spindle orientation in a Notch-dependent manner. *Cell Rep* **4**, 110–123, doi: 10.1016/j.celrep.2013.05.044 (2013).
48. Elowe, S. Bub1 and BubR1: at the interface between chromosome attachment and the spindle checkpoint. *Mol Cell Biol* **31**, 3085–3093, doi: 10.1128/MCB.05326-11 (2011).
49. Jiang, J., Mohan, P. & Maxwell, C. A. The cytoskeletal protein RHAMM and ERK1/2 activity maintain the pluripotency of murine embryonic stem cells. *PLoS One* **8**, e73548, doi: 10.1371/journal.pone.0073548 (2013).
50. Han, Y. K. *et al.* A possible usage of a CDK4 inhibitor for breast cancer stem cell-targeted therapy. *Biochem Biophys Res Commun* **430**, 1329–1333, doi: 10.1016/j.bbrc.2012.10.119 (2013).
51. Lee, C. G. *et al.* Roles of 14-3-3eta in mitotic progression and its potential use as a therapeutic target for cancers. *Oncogene* **32**, 1560–1569, doi: 10.1038/onc.2012.170 (2013).
52. Park, G. Y. *et al.* 14-3-3 eta depletion sensitizes glioblastoma cells to irradiation due to enhanced mitotic cell death. *Cancer Gene Ther* **21**, 158–163, doi: 10.1038/cgt.2014.11 (2014).

Acknowledgements

This work was supported by the National Research Foundation of Korea (DIRAMS) grant funded by the Korea government (MSIP) (50597–2014 & 50491–2015). We thank Min Young Kim, and Min Su Ju for administrative support.

Author Contributions

C.G.L, J.Y.H. and Y.K.H. designed and wrote the manuscript. G.-Y.P. and S.D.K. performed the experiments. J.S.K. and W.S.J. analyzed the data and made scientific comments. All authors reviewed the manuscript.

Additional Information

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Yoon Han, J. *et al.* Bub1 is required for maintaining cancer stem cells in breast cancer cell lines. *Sci. Rep.* **5**, 15993; doi: 10.1038/srep15993 (2015).



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>